{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T05:01:06Z","timestamp":1778216466825,"version":"3.51.4"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T00:00:00Z","timestamp":1768348800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T00:00:00Z","timestamp":1768348800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100006752","name":"Universidade do Porto","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006752","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BioDrugs"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s40259-025-00762-w","type":"journal-article","created":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T16:21:15Z","timestamp":1768407675000},"page":"263-278","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The Role of OX40 Pathway Inhibition as a New Therapeutic Strategy for Atopic Dermatitis"],"prefix":"10.1007","volume":"40","author":[{"given":"David","family":"Oliveira dos Santos","sequence":"first","affiliation":[]},{"given":"Amir","family":"Mohamed","sequence":"additional","affiliation":[]},{"given":"Adam","family":"Mohamed","sequence":"additional","affiliation":[]},{"given":"Jos\u00e9 Miguel","family":"Alvarenga","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0404-0870","authenticated-orcid":false,"given":"Tiago","family":"Torres","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2026,1,14]]},"reference":[{"issue":"Suppl. 1","key":"762_CR1","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1159\/000370220","volume":"66","author":"S Nutten","year":"2015","unstructured":"Nutten S. Atopic dermatitis: global epidemiology and risk factors. Ann Nutr Metab. 2015;66(Suppl. 1):8\u201316. https:\/\/doi.org\/10.1159\/000370220.","journal-title":"Ann Nutr Metab"},{"key":"762_CR2","doi-asserted-by":"publisher","unstructured":"Barbarot S, Auziere S, Gadkari A, et al. Epidemiology of atopic dermatitis in adults: results from an international survey. Allergy. 2018;73(6):1284\u201393. https:\/\/doi.org\/10.1111\/all.13401.","DOI":"10.1111\/all.13401"},{"key":"762_CR3","unstructured":"Fauci AS, Kasper DL, Hauser SL, Jameson JL, Loscalzo J. Atopic dermatitis. In: Harrison\u2019s principles of internal medicine. Vol 1. 20th ed. New York: McGraw-Hill Education; 2018."},{"key":"762_CR4","doi-asserted-by":"publisher","unstructured":"Davidson WF, Leung DYM, Beck LA, et al. Report from the National Institute of Allergy and Infectious Diseases workshop on \u201cAtopic dermatitis and the atopic march: Mechanisms and interventions.\u201d J Allergy Clin Immunol. 2019;143(3):894\u2013913. https:\/\/doi.org\/10.1016\/j.jaci.2019.01.003","DOI":"10.1016\/j.jaci.2019.01.003"},{"issue":"2","key":"762_CR5","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.jaad.2013.10.010","volume":"70","author":"LF Eichenfield","year":"2014","unstructured":"Eichenfield LF, Tom WL, Chamlin SL, et al. Guidelines of care for the management of atopic dermatitis. J Am Acad Dermatol. 2014;70(2):338\u201351. https:\/\/doi.org\/10.1016\/j.jaad.2013.10.010.","journal-title":"J Am Acad Dermatol"},{"issue":"9","key":"762_CR6","doi-asserted-by":"publisher","first-page":"606","DOI":"10.20344\/amp.11963","volume":"32","author":"T Torres","year":"2019","unstructured":"Torres T, Ferreira EO, Gon\u00e7alo M, Mendes-Bastos P, Selores M, Filipe P. Update on atopic dermatitis. Acta Med Port. 2019;32(9):606\u201313. https:\/\/doi.org\/10.20344\/amp.11963.","journal-title":"Acta Med Port"},{"issue":"Suppl. 1","key":"762_CR7","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1159\/000370226","volume":"66","author":"C Lifschitz","year":"2015","unstructured":"Lifschitz C. The impact of atopic dermatitis on quality of life. Ann Nutr Metab. 2015;66(Suppl. 1):34\u201340. https:\/\/doi.org\/10.1159\/000370226.","journal-title":"Ann Nutr Metab"},{"issue":"12","key":"762_CR8","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14122753","volume":"14","author":"AM L\u00e9","year":"2022","unstructured":"L\u00e9 AM, Torres T. OX40-OX40L inhibition for the treatment of atopic dermatitis: focus on rocatinlimab and amlitelimab. Pharmaceutics. 2022;14(12):2753. https:\/\/doi.org\/10.3390\/pharmaceutics14122753.","journal-title":"Pharmaceutics"},{"issue":"11","key":"762_CR9","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-024-02095-4","volume":"84","author":"JM Alvarenga","year":"2024","unstructured":"Alvarenga JM, Bieber T, Torres T. Emerging biologic therapies for the treatment of atopic dermatitis. Drugs. 2024;84(11):1379. https:\/\/doi.org\/10.1007\/s40265-024-02095-4.","journal-title":"Drugs"},{"key":"762_CR10","unstructured":"UpToDate. Waltham, MA: UpToDate, Inc.; Treatment of atopic dermatitis (eczema). Available from: https:\/\/www.uptodate.com\/contents\/treatment-of-atopicdermatitiseczema?search=dermatite%20atopica&source=search_result&selectedTitle=3%7E150&usage_type=default&display_rank=1#H903644714. [Accessed 23 Dec 2024]."},{"issue":"12","key":"762_CR11","doi-asserted-by":"publisher","first-page":"2558","DOI":"10.1111\/jdv.19391","volume":"37","author":"E Guttman-Yassky","year":"2023","unstructured":"Guttman-Yassky E, Silverberg JI, Tha\u00e7i D, et al. Upadacitinib treatment withdrawal and retreatment in patients with moderate-to-severe atopic dermatitis: results from a phase 2b, randomized, controlled trial. J Eur Acad Dermatol Venereol. 2023;37(12):2558\u201368. https:\/\/doi.org\/10.1111\/jdv.19391.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"762_CR12","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.jaad.2021.05.075","volume":"86","author":"A Blauvelt","year":"2022","unstructured":"Blauvelt A, Silverberg JI, Lynde CW, et al. Abrocitinib induction, randomized withdrawal, and retreatment in patients with moderate-to-severe atopic dermatitis: results from the JAK1 atopic dermatitis efficacy and safety (JADE) REGIMEN phase 3 trial. J Am Acad Dermatol. 2022;86(1):104\u201312. https:\/\/doi.org\/10.1016\/j.jaad.2021.05.075.","journal-title":"J Am Acad Dermatol"},{"key":"762_CR13","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.19574","volume":"184","author":"A Wollenberg","year":"2021","unstructured":"Wollenberg A, Blauvelt A, Guttman-Yassky E, et al. Tralokinumab for moderate-tosevere atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2). Br J Dermatol. 2021;184:386387. https:\/\/doi.org\/10.1111\/bjd.19574.","journal-title":"Br J Dermatol"},{"issue":"12","key":"762_CR14","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1001\/jamadermatol.2019.3617","volume":"155","author":"M Worm","year":"2019","unstructured":"Worm M, Simpson EL, Tha\u00e7i D, et al. Efficacy and safety of multiple dupilumab dose regimens after initial successful treatment in patients with atopic dermatitis: a randomized clinical trial. JAMA Dermatol. 2019;155(12):1375\u201383. https:\/\/doi.org\/10.1001\/jamadermatol.2019.3617.","journal-title":"JAMA Dermatol"},{"issue":"12","key":"762_CR15","doi-asserted-by":"publisher","first-page":"3197","DOI":"10.1007\/s13555-024-01308-8","volume":"14","author":"A Abdelhalim","year":"2024","unstructured":"Abdelhalim A, Orhan M, Mohamed Y, et al. A narrative review of the OX40-OX40L pathway as a potential therapeutic target in atopic dermatitis: focus on rocatinlimab and amlitelimab. Dermatol Ther (Heidelb). 2024;14(12):3197. https:\/\/doi.org\/10.1007\/s13555-024-01308-8.","journal-title":"Dermatol Ther (Heidelb)."},{"issue":"3","key":"762_CR16","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.det.2017.02.006","volume":"35","author":"K Malik","year":"2017","unstructured":"Malik K, Heitmiller KD, Czarnowicki T. An update on the pathophysiology of atopic dermatitis. Dermatol Clin. 2017;35(3):317\u201326. https:\/\/doi.org\/10.1016\/j.det.2017.02.006.","journal-title":"Dermatol Clin"},{"issue":"2","key":"762_CR17","doi-asserted-by":"publisher","first-page":"84","DOI":"10.2500\/AAP.2019.40.4202","volume":"40","author":"J Kim","year":"2019","unstructured":"Kim J, Kim BE, Leung DYM. Pathophysiology of atopic dermatitis: clinical implications. Allergy Asthma Proc. 2019;40(2):84. https:\/\/doi.org\/10.2500\/AAP.2019.40.4202.","journal-title":"Allergy Asthma Proc"},{"issue":"7","key":"762_CR18","doi-asserted-by":"publisher","DOI":"10.3390\/cells13070587","volume":"13","author":"K Sadrolashrafi","year":"2024","unstructured":"Sadrolashrafi K, Guo L, Kikuchi R, et al. An OX-Tra\u2019Ordinary tale: the role of OX40 and OX40L in atopic dermatitis. Cells. 2024;13(7):587. https:\/\/doi.org\/10.3390\/cells13070587.","journal-title":"Cells"},{"issue":"12","key":"762_CR19","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10122578","volume":"10","author":"M Furue","year":"2021","unstructured":"Furue M, Furue M. OX40L-OX40 signaling in atopic dermatitis. J Clin Med. 2021;10(12):2578. https:\/\/doi.org\/10.3390\/jcm10122578.","journal-title":"J Clin Med"},{"key":"762_CR20","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljae230","author":"E Guttman-Yassky","year":"2024","unstructured":"Guttman-Yassky E, Croft M, Geng B, et al. The role of OX40 ligand\/OX40 axis signalling in atopic dermatitis. Br J Dermatol. 2024. https:\/\/doi.org\/10.1093\/bjd\/ljae230.","journal-title":"Br J Dermatol"},{"key":"762_CR21","unstructured":"GlobeNewswire. Inmagene reports positive topline results of IMG-007, a nondepleting anti-OX40 monoclonal antibody with an extended half-life for the treatment of atopic dermatitis. Available from: https:\/\/www.globenewswire.com\/news-release\/2025\/01\/09\/3007096\/0\/en\/Inmagene-Reports-Positive-Topline-Results-of-IMG-007-aNondepleting-Anti-OX40-Monoclonal-Antibody-with-an-Extended-Half-Life-for-theTreatment-of-Atopic-Dermatitis.html. (Accessed 1 Mar 2025)."},{"key":"762_CR22","unstructured":"Astria Therapeutics. Astria Therapeutics announces positive initial results from phase 1a trial of STAR-0310. Boston (MA): Astria Therapeutics; 2025 Sep 9. Available from: https:\/\/ir.astriatx.com\/news-releases\/news-release-details\/astria-therapeutics-announces-positive-initial-results-phase-1a. (Accessed 9 Dec 2025)."},{"key":"762_CR23","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1002\/cpt.2539","volume":"111","author":"M Saghari","year":"2022","unstructured":"Saghari M, Gal P, Gilbert S, et al. OX40L inhibition suppresses KLH-driven immune responses in healthy volunteers: a randomized controlled trial demonstrating proof-ofpharmacology for KY1005. Clin Pharmacol Ther. 2022;111:1121\u201332. https:\/\/doi.org\/10.1002\/cpt.2539.","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"762_CR24","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1093\/bjd\/ljad240","volume":"189","author":"S Weidinger","year":"2023","unstructured":"Weidinger S, Bieber T, Cork MJ, et al. Safety and efficacy of amlitelimab, a fully human nondepleting, noncytotoxic anti-OX40 ligand monoclonal antibody, in atopic dermatitis: results of a phase IIa randomized placebo-controlled trial. Br J Dermatol. 2023;189(5):531\u20139. https:\/\/doi.org\/10.1093\/bjd\/ljad240.","journal-title":"Br J Dermatol"},{"issue":"4","key":"762_CR25","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1016\/j.jaci.2024.10.031","volume":"155","author":"S Weidinger","year":"2024","unstructured":"Weidinger S, Blauvelt A, Papp KA, Reich A, Lee CH. Phase 2b randomized clinical trial of amlitelimab, an anti-OX40 ligand antibody, in patients with moderate-to-severe atopic dermatitis. J Allergy Clin Immunol. 2024;155(4):1264\u201375. https:\/\/doi.org\/10.1016\/j.jaci.2024.10.031.","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"762_CR26","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1007\/s40257-02300838-9","volume":"25","author":"M Croft","year":"2024","unstructured":"Croft M, Esfandiari E, Chong C, et al. OX40 in the pathogenesis of atopic dermatitis: a new therapeutic target. Am J Clin Dermatol. 2024;25(3):447\u201361. https:\/\/doi.org\/10.1007\/s40257-02300838-9.","journal-title":"Am J Clin Dermatol"},{"issue":"2","key":"762_CR27","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.jdermsci.2020.06.005","volume":"99","author":"H Nakagawa","year":"2020","unstructured":"Nakagawa H, Iizuka H, Nemoto O, et al. Safety, tolerability and efficacy of repeated intravenous infusions of KHK4083, a fully human anti-OX40 monoclonal antibody, in Japanese patients with moderate to severe atopic dermatitis. J Dermatol Sci. 2020;99(2):82\u20139. https:\/\/doi.org\/10.1016\/j.jdermsci.2020.06.005.","journal-title":"J Dermatol Sci"},{"issue":"10372","key":"762_CR28","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/S0140-6736(22)02037-2","volume":"401","author":"E Guttman-Yassky","year":"2023","unstructured":"Guttman-Yassky E, Simpson EL, Reich K, et al. An anti-OX40 antibody to treat moderate-to-severe atopic dermatitis: a multicentre, double-blind, placebo-controlled phase 2b study. Lancet. 2023;401(10372):204\u201314. https:\/\/doi.org\/10.1016\/S0140-6736(22)02037-2.","journal-title":"Lancet"},{"key":"762_CR29","unstructured":"Guttman-Yassky E, Kabashima K, Worm M, Luna PC, Hong HC, Chovatiya R, et al. Efficacy and safety of rocatinlimab for the treatment of moderate-to-severe atopic dermatitis in ROCKET-IGNITE and ROCKET-HORIZON: two global, double-blind, placebo-controlled, randomised phase 3 clinical trials. Lancet. 2025. (S0140-6736(25)01865-3)."},{"key":"762_CR30","unstructured":"ClinicalTrials.gov. A study assessing rocatinlimab in combination with topical corticosteroid and\/or topical calcineurin inhibitors in adult participants with moderate-to-severe atopic dermatitis (AD). Available from: https:\/\/clinicaltrials.gov\/study\/NCT05724199?cond=Atopic%20Dermatitis&intr=rocatinlimab&rank=7. (Accessed 19 Feb 2025)."},{"key":"762_CR31","unstructured":"Health Research Authority. A phase 3 study of rocatinlimab, corticosteroids and\/or calcineurin inhibitors in AD (ROCKET-Shuttle). Available from: https:\/\/www.hra.nhs.uk\/planning-and-improving-research\/application-summaries\/researchsummaries\/a-phase-3-study-of-roctinlimab-corticosteroids-andor-calcineurin-inhibitors-in-adrocket-shuttle\/. (Accessed 19 Feb 2025)."},{"key":"762_CR32","unstructured":"ClinicalTrials.gov. A study assessing rocatinlimab on vaccine antibody response in moderate-to-severe atopic dermatitis (AD) (ROCKET - VOYAGER). Available from: https:\/\/clinicaltrials.gov\/study\/NCT05899816?cond=rocatinlimab&intr=nct05899816&rank=1. (Accessed 16 Mar 2025)."},{"key":"762_CR33","doi-asserted-by":"crossref","unstructured":"Gudi G, Vinu CA, Sunitha GN, et al. Clinical pharmacokinetics and immunogenicity of GBR 830, a first-in-class humanized monoclonal antibody inhibiting OX40 to treat atopic dermatitis. Presented at the 7th Annual International Investigative Dermatology Meeting May 16\u201319, 2018, Orlando, FL.","DOI":"10.1016\/j.jid.2018.03.1107"},{"key":"762_CR34","unstructured":"ClinicalTrials.gov. To assess the safety and activity of GBR 830, compared to placebo, in adults with moderate-to-severe atopic dermatitis. Available from: https:\/\/clinicaltrials.gov\/study\/NCT02683928. (Accessed 12 Dec 2025)."},{"issue":"2","key":"762_CR35","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1016\/j.jaci.2018.11.053","volume":"144","author":"E Guttman-Yassky","year":"2019","unstructured":"Guttman-Yassky E, Pavel AB, Zhou L, et al. GBR 830, an anti-OX40, improves skin gene signatures and clinical scores in patients with atopic dermatitis. J Allergy Clin Immunol. 2019;144(2):482-93.e7. https:\/\/doi.org\/10.1016\/j.jaci.2018.11.053.","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"762_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacig.2023.100195","volume":"3","author":"B Rewerska","year":"2024","unstructured":"Rewerska B, Sher LD, Alpizar S, et al. Phase 2b randomized trial of OX40 inhibitor telazorlimab for moderate-to-severe atopic dermatitis. J Allergy Clin Immunol Glob. 2024;3(1):100195. https:\/\/doi.org\/10.1016\/j.jacig.2023.100195.","journal-title":"J Allergy Clin Immunol Glob"},{"key":"762_CR37","unstructured":"Business Wire. San Francisco: Business Wire; 2025. Astria Therapeutics announces initiation of phase 1a trial of STAR-0310, a potential best-in-class monoclonal antibody OX40 antagonist for the treatment of atopic dermatitis. Available from: https:\/\/www.businesswire.com\/news\/home\/20250123072294\/en\/Astria-TherapeuticsAnnounces-Initiation-of-Phase-1a-Trial-of-STAR-0310-a-Potential-Best-in-Class-MonoclonalAntibody-OX40-Antagonist-for-the-Treatment-of-Atopic-Dermatitis. (Accessed 14 Mar 2025)."},{"issue":"Suppl. 2","key":"762_CR38","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljae266.076","volume":"191","author":"Y Shen","year":"2024","unstructured":"Shen Y, Lin Z, Guo C, Nair A, Lu Y, Silverberg JI. IMG-007, a nondepleting OX40 monoclonal antibody with an extended half-life, improves skin lesions in adults with moderateto-severe atopic dermatitis: interim results from a phase 2a trial. Br J Dermatol. 2024;191(Suppl. 2):e76. https:\/\/doi.org\/10.1093\/bjd\/ljae266.076.","journal-title":"Br J Dermatol"},{"key":"762_CR39","doi-asserted-by":"publisher","DOI":"10.2340\/actadv.v102.3932","volume":"102","author":"M Augustin","year":"2022","unstructured":"Augustin M, Costanzo A, Pink A, et al. Real-world treatment patterns and treatment benefits among adult patients with atopic dermatitis: results from the Atopic Dermatitis Patient Satisfaction and Unmet Need Survey. Acta Derm Venereol. 2022;102:adv3932. https:\/\/doi.org\/10.2340\/actadv.v102.3932.","journal-title":"Acta Derm Venereol"},{"key":"762_CR40","unstructured":"ClinicalTrials.gov. A study to evaluate the efficacy and safety of subcutaneous amlitelimab monotherapy compared with placebo in participants aged 12 years and older with moderate-to-severe atopic dermatitis. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06130566?cond=Atopic%20Dermatitis&intr=amlitelimab&rank=2. (Accessed 14 Apr 2025)."},{"key":"762_CR41","unstructured":"ClinicalTrials.gov. A study to evaluate the efficacy and safety of subcutaneous amlitelimab monotherapy compared with placebo in participants aged 12 years and older with moderate-to-severe atopic dermatitis (COAST 2). Available from: https:\/\/clinicaltrials.gov\/study\/NCT06181435?cond=Atopic%20Dermatitis&intr=amlitelimab&rank=3. (Accessed 4 Apr 2025)."},{"key":"762_CR42","unstructured":"ClinicalTrials.gov. A study to evaluate the efficacy and safety of subcutaneous amlitelimab in participants aged 12 years and older with moderate-to-severe atopic dermatitis on background topical corticosteroids. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06224348?cond=Atopic%20Dermatitis&intr=amlitelimab&rank=7. (Accessed 4 Apr 2025)."},{"key":"762_CR43","unstructured":"ClinicalTrials.gov. A study to evaluate the treatment response and safety of two dose regimens of subcutaneous amlitelimab monotherapy compared with treatment withdrawal in participants aged 12 years and older with moderate-to-severe atopic dermatitis. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06407934?cond=Atopic%20Dermatitis&intr=amlitelimab&rank=4. (Accessed 4 Apr 2025)."},{"key":"762_CR44","unstructured":"ClinicalTrials.gov. A study to evaluate the efficacy and safety of subcutaneous amlitelimab on background topical corticosteroids therapy in participants aged 12 years and older with moderate-to-severe AD who have had an inadequate response to prior biologic therapy or an oral JAK inhibitor. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06241118?cond=Atopic%20Dermatitis&intr=amlitelimab&rank=9. (Accessed 2025\/04\/14)."},{"key":"762_CR45","unstructured":"ClinicalTrials.gov. Open label, long-term study evaluating safety and efficacy of subcutaneous amlitelimab in participants aged 12 years and older with moderate to severe atopic dermatitis. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05769777?cond=Atopic%20Dermatitis&intr=amlitelimab&rank=1. (Accessed 14 Apr 2025)."},{"key":"762_CR46","unstructured":"ClinicalTrials.gov. Long-term safety and efficacy evaluation of amlitelimab in participants of previous amlitelimab moderate to severe atopic dermatitis clinical trials. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05492578?cond=Atopic%20Dermatitis&intr=amlitelimab&rank=8. (Accessed 14 Apr 2025)."},{"key":"762_CR47","unstructured":"ClinicalTrials.gov. A study to investigate vaccine responses in subcutaneous amlitelimab treated atopic dermatitis participants aged 18 years and older compared with placebo. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06015308?cond=Atopic%20Dermatitis&intr=amlitelimab&rank=5. (Accessed 14 Apr 2025)."},{"key":"762_CR48","unstructured":"ClinicalTrials.gov. A study to assess the safety, tolerability, and efficacy of rocatinlimab in adolescent participants with moderate-to-severe atopic dermatitis (AD). Available from: https:\/\/clinicaltrials.gov\/study\/NCT05633355?cond=Atopic%20Dermatitis&intr=rocatinlimab&rank=2. (Accessed 19 Feb 2025)."},{"key":"762_CR49","unstructured":"ClinicalTrials.gov. A study to evaluate rocatinlimab (AMG 451) in adolescent participants with moderate-to-severe atopic dermatitis (AD). Available from: https:\/\/clinicaltrials.gov\/study\/NCT05704738?cond=Atopic%20Dermatitis&intr=AMG%20451&rank=4#study-plan. (Accessed 19 Feb 2025)."},{"key":"762_CR50","unstructured":"ClinicalTrials.gov. A study with self-administered rocatinlimab in adolescent and adult participants with moderate-to-severe AD. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06224192?cond=Atopic%20Dermatitis&intr=AMG%20451&rank=5#study-plan. (Accessed 19 Feb 2025)."},{"key":"762_CR51","unstructured":"ClinicalTrials.gov. A study to assess long-term safety, tolerability, and efficacy of rocatinlimab in adult and adolescent participants with moderate-to-severe atopic dermatitis (AD). Available from: https:\/\/clinicaltrials.gov\/study\/NCT05882877?cond=Atopic%20Dermatitis&intr=rocatinlimab&rank=8. (Accessed 14 Apr 2025)."},{"key":"762_CR52","unstructured":"Clinical Trials Arena. London: Netwise Publishing Ltd; 2025. Available from: https:\/\/www.clinicaltrialsarena.com\/news\/inmagene-study-kickstart-proof-of-concept-img007\/. (Accessed 14 Apr 2025)."},{"issue":"7","key":"762_CR53","doi-asserted-by":"publisher","DOI":"10.3390\/cells13070587","volume":"13","author":"N Biris","year":"2024","unstructured":"Biris N, Macoin J, Carretero L, Perez C, Zhao C. Development and characterization of STAR-0310: a novel OX40 antagonistic monoclonal antibody. Cells. 2024;13(7):0587. https:\/\/doi.org\/10.3390\/cells13070587.","journal-title":"Cells"},{"key":"762_CR54","unstructured":"Apogee Therapeutics. Apogee Therapeutics announces positive interim phase\u202f1 results from the APG990 healthy volunteer trial, unlocking potential maintenance dosing every three and six months for APG279 (APG777 + APG990). News Release, 3 Mar\u202f2025. Apogee Therapeutics. Available from: https:\/\/investors.apogeetherapeutics.com. Accessed 1 Aug 2025."},{"key":"762_CR55","unstructured":"Apogee Therapeutics, Inc. Apogee Therapeutics announces positive interim phase 1 results from the APG990 healthy volunteer trial, unlocking potential maintenance dosing every three and six months for APG279 (APG777 + APG990). GlobeNewswire, 3 Mar. 2025. Apogee Therapeutics, Inc. Available from: https:\/\/seekingalpha.com. Accessed 1 Aug 2025."},{"key":"762_CR56","unstructured":"ClinicalTrials.gov. A study to evaluate the safety, tolerability, pharmacokinetics, and immunogenicity of STAR-0310 in healthy adult participants. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06782477. (Accessed 1 Aug 2025)."}],"container-title":["BioDrugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-025-00762-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40259-025-00762-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-025-00762-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T06:01:26Z","timestamp":1774418486000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40259-025-00762-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,14]]},"references-count":56,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["762"],"URL":"https:\/\/doi.org\/10.1007\/s40259-025-00762-w","relation":{},"ISSN":["1173-8804","1179-190X"],"issn-type":[{"value":"1173-8804","type":"print"},{"value":"1179-190X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,14]]},"assertion":[{"value":"14 December 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No funding was received for the preparation of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"David Oliveira dos Santos, Amir Mohamed, Adam Mohamed, and Jos\u00e9 Miguel Alvarenga have no conflicts of interest that are directly relevant to the content of this article. Tiago Torres has received consultancy and\/or speaker\u2019s honoraria from and\/or participated in clinical trials sponsored by AbbVie, Amgen, Almirall, Arena Pharmaceuticals, Biocad, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Fresenius-Kabi, Janssen, LEO Pharma, Eli Lilly, MSD, Mylan, Novartis, Pfizer, Samsung-Bioepis, Sanofi-Genzyme, Sandoz, and UCB.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest\/Competing Interests"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"All named authors (DOS, AM, AM, JMA, and TT) meet the International Committee of Medical Journal Editors criteria for authorship for this article, take responsibility for the integrity of the work as a whole, and have given the final approval for the version to be published.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}